omeprazole and Esophagitis, Peptic studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Esophagitis, Peptic: INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM.

Research Excerpts

Excerpt	Relevance	Reference
"We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study."	9.12	Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006)
" This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)."	9.11	Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004)
"To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis."	9.11	Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005)
": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily."	9.10	Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003)
"To assess the efficacy of omeprazole in treating irritable infants with gastroesophageal reflux and/or esophagitis."	9.10	Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. ( Davidson, GP; Heddle, ML; Hirte, C; Lines, DR; Moore, DJ; Tao, BS, 2003)
"Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom."	9.09	Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999)
"To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)."	9.09	Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000)
"We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)."	9.09	Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000)
"Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n = 509)."	9.08	Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A, 1997)
"This paper is a meta-analysis of 30 published, double-blind clinical trials comparing omeprazole with ranitidine or cimetidine for the treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis."	8.79	Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. ( Carlsson, R; Eriksson, S; Långström, G; Naesdal, J; Rikner, L, 1995)
"Omeprazole regulates gastric acid secretion and is an effective treatment of acute duodenal ulcer and reflux oesophagitis, achieving more rapid healing and symptomatic relief than histamine H 2-receptor antagonists."	8.78	Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis. ( Barradell, LB; McTavish, D, 1993)
" This study evaluated the inhibitory action of apigenin-7-O-beta-D-glucuronopyranoside (AGC), apigenin, and omeprazole on reflux oesophagitis and gastritis in rats."	7.73	The effects of apigenin-7-O-beta-D-glucuronopyranoside on reflux oesophagitis and gastritis in rats. ( Bai, KL; Choi, HJ; Ham, I; Jeong, JH; Min, YS; Park, SY; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2005)
"This study evaluated the inhibitory action of luteolin-7-O-beta-D-glucuronopyranoside, luteolin which was isolated from Salix gilgiana leaves, and omeprazole on reflux esophagitis and gastritis in rats."	7.73	The effect of luteolin-7-O-beta-D-glucuronopyranoside on gastritis and esophagitis in rats. ( Bai, KL; Ham, I; Kim, JH; Lee, YJ; Min, YS; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2006)
"Multiple gastric polyps have been reported to occur in adults receiving omeprazole therapy."	7.71	Gastric polyps and nodules in children receiving long-term omeprazole therapy. ( Israel, DM; Pashankar, DS, 2002)
"In this randomized multicenter trial with a 5-year followup, we found antireflux surgery to be more effective than omeprazole in controlling gastroesophageal reflux disease as measured by the treatment failure rates."	7.71	Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. ( Carlsson, J; Hatlebakk, JG; Julkonen, R; Lamm, M; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Pedersen, SA; Wiklund, I, 2001)
"Omeprazole is an effective long-term drug for gastroesophageal reflux disease after failed fundoplication in children."	7.71	Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. ( Blair, GK; Israel, DM; Pashankar, D, 2001)
" pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study."	7.70	Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999)
"A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole."	7.69	Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997)
"A total of 143 patients with peptic ulceration of the duodenum, stomach and oesophagus who did not respond to 3 or more months of high-dose treatment with ranitidine, 450 mg or more daily, were treated with oral omeprazole, 40 mg daily."	7.68	Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. ( Brunner, GH; Creutzfeldt, W; Lamberts, R, 1990)
" To investigate the effect of omeprazole and higher-than-presently-recommended doses of H2-blockers, we evaluated gastric acidity and gastroesophageal reflux in 17 patients with severe-moderate esophagitis before and after treatment with 300 mg ranitidine twice daily or 20 mg omeprazole once daily."	7.68	Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. ( Fiorucci, S; Morelli, A; Santucci, L, 1990)
"Gastroesophageal reflux disease (GERD) is a common disorder."	6.73	Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment. ( Lin, SR; Xue, Y; Zhou, LY, 2008)
"Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being."	6.71	Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003)
"Both rabeprazole doses were significantly superior to placebo in preventing relapse of heartburn frequency and improving patient quality of life."	6.71	Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005)
"Pantoprazole once daily was superior to nizatidine b."	6.70	Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001)
"Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall."	6.69	Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000)
"Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+."	6.68	One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997)
"More than 13,000 individuals with duodenal ulcer, gastric ulcer or reflux oesophagitis have now taken part in controlled clinical studies with omeprazole."	6.16	The clinical utility and safety of omeprazole. ( Walan, A, 1989)
"Omeprazole is a proton pump inhibitor which reduces both basal and stimulated gastric acid secretion by inhibiting the parietal cell enzyme H(+)-K(+)-adenosine triphosphatase."	5.33	[Anaphylaxis caused by omeprazole]. ( Bauer, C; Fackler, I; Kamann, S; Przybilla, B, 2006)
"The therapeutic approach to gastroesophageal reflux disease (GERD) in intellectually disabled individuals has not been studied extensively."	5.30	Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. ( Bohmer, CJ; Devillé, WL; Klinkenberg-Knol, EC; Meuwissen, SG; Niezen-de Boer, MC; Tuynman, HA; Voskuil, JH, 1997)
"Therefore, we diagnosed bronchial asthma associated with reflux esophagitis and gastroduodenal ulcer."	5.29	[A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1994)
"In patients with Barrett's esophagus, LES pressure was considerably lower and percentage exposure to acid was considerably higher than in either patients with esophagitis or controls (p less than 0."	5.28	Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. ( Farroni, F; Fiorucci, S; Morelli, A; Pelli, MA; Santucci, L, 1989)
"To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)."	5.15	Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011)
"We sought to evaluate safety and efficacy of IV pantoprazole when used as initial therapy in patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) in a double-blind, placebo-controlled, randomized, parallel-group study."	5.12	Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. ( Field, B; Hogan, DL; Lynn, RB; Metz, DC; Pratha, V, 2006)
" This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)."	5.11	Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004)
"To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis."	5.11	Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005)
"Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment."	5.11	Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005)
"This study aimed to determine whether dysphagia associated with gastroesophageal reflux disease was effectively treated with rabeprazole, a proton pump inhibitor."	5.11	Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. ( Danjo, A; Fujimoto, K; Hara, M; Iwakiri, R; Kikkawa, A; Oda, K; Ootani, A; Sakata, H; Shimoda, R; Tsunada, S; Watanabe, K, 2005)
"Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease."	5.10	Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. ( Bochenek, W; DeVault, K; Kovacs, TO; Miska, D; Wilcox, CM, 2002)
": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily."	5.10	Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003)
"To compare the efficacy and tolerability of pantoprazole 40 mg and omeprazole MUPS 40 mg in patients with moderate to severe gastroesophageal reflux disease (GERD)."	5.10	Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. ( Bohuschke, M; Costa Neves, B; Fumagalli, I; Gatz, G; Körner, T; Schütze, K; van Leendert, RJ, 2003)
"To assess the efficacy of omeprazole in treating irritable infants with gastroesophageal reflux and/or esophagitis."	5.10	Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. ( Davidson, GP; Heddle, ML; Hirte, C; Lines, DR; Moore, DJ; Tao, BS, 2003)
"Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis."	5.10	Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003)
"The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health-related quality of life and safety in endoscopically confirmed erosive gastro-oesophageal reflux disease treated with rabeprazole."	5.10	Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002)
" Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD)."	5.10	Integrated acidity and rabeprazole pharmacology. ( Barth, JA; Gardner, JD; Hahne, WF; Perdomo, C; Robinson, M; Rodriguez-Stanley, S; Sloan, S, 2002)
"Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom."	5.09	Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999)
"The aim of this study was to compare the efficacy and tolerability of low dose pantoprazole (20 mg) (a gastric proton pump inhibitor) with standard dose ranitidine (300 mg) (a histamine-receptor antagonist), in their ability to relieve symptoms and heal oesophageal lesions associated with gastrooesophageal reflux disease (GORD)."	5.09	Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. ( Bethke, T; de K Grundling, H; Fischer, R; O'Keefe, SJ; Retief, FJ; Theron, I; van Rensburg, CJ; van Zyl, JH, 2000)
"To compare the efficacy of 20 mg with 40 mg pantoprazole in maintaining symptomatic and endoscopic remission in patients with gastro-oesophageal reflux disease (GORD)."	5.09	Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. ( Fumagalli, I; Hotz, J; Lühmann, R; Plein, K; Schneider, A; Wurzer, H, 2000)
"The aim of this dose-response study was to compare the effectiveness of 10 mg, 20 mg, and 40 mg of pantoprazole with that of placebo tablets in the healing and symptom relief of gastroesophageal reflux disease associated with erosive esophagitis, and to determine the optimal dose."	5.09	Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. ( Bochenek, W; Richter, JE, 2000)
"We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)."	5.09	Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000)
"Omeprazole is well tolerated, highly effective, and safe for treatment of erosive esophagitis and symptoms of gastroesophageal reflux in children, including children in whom antireflux surgery or other medical therapy has failed."	5.09	Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. ( Dalväg, A; Hassall, E; Israel, D; Junghard, O; Lundborg, P; Radke, M; Shepherd, R; Sköld, B, 2000)
"Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n = 509)."	5.08	Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A, 1997)
" However, lansoprazole appears to have a more rapid onset of reduction of acid gastro-oesophageal reflux than omeprazole over a 48 h period."	5.08	Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. ( Burnham, WR; Kamm, MA; Newton, M, 1998)
"The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief."	4.95	Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017)
"The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis."	4.89	Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. ( Satoh, H, 2013)
"In uncontrolled clinical trials and case reports to date, omeprazole has been effective and well tolerated for the acute and chronic treatment of esophageal and peptic ulcer disease in children, particularly those who had failed to respond to previous treatment with histamine2-receptor antagonists."	4.81	A review of omeprazole use in the treatment of acid-related disorders in children. ( Katona, BG; Levine, D; Souney, PE; Walters, JK; Zimmermann, AE, 2001)
" A daily dose of 30 mg lansoprazole reduced epigastric pain faster than omeprazole 20 mg daily in patients with peptic ulcer disease but healing rates at 4 and 8 weeks were similar with both agents at these dosages."	4.81	Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. ( Gremse, DA, 2001)
"This paper is a meta-analysis of 30 published, double-blind clinical trials comparing omeprazole with ranitidine or cimetidine for the treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis."	4.79	Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. ( Carlsson, R; Eriksson, S; Långström, G; Naesdal, J; Rikner, L, 1995)
"Omeprazole regulates gastric acid secretion and is an effective treatment of acute duodenal ulcer and reflux oesophagitis, achieving more rapid healing and symptomatic relief than histamine H 2-receptor antagonists."	4.78	Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis. ( Barradell, LB; McTavish, D, 1993)
"Omeprazole was administered for up to 6 years in 859 patients for 'prevention of relapse in patients with poorly responsive peptic ulcer or reflux oesophagitis'."	4.78	Safety experience from long-term treatment with omeprazole. ( Joelson, IB; Joelson, S; Lundborg, P; Walan, A; Wallander, MA, 1992)
"Studies with short-term administration of omeprazole in patients with erosive or ulcerative reflux oesophagitis have demonstrated that strong inhibition of gastric acid secretion will become the therapy of choice for these patients."	4.77	Omeprazole in the short-term treatment of reflux oesophagitis. ( Jansen, JB; Lamers, CB, 1989)
"Arguments in favour of the use of omeprazole outweight the arguments against its use in the treatment of all peptic disorders--duodenal ulcer, gastric ulcer and reflux oesophagitis."	4.77	Omeprazole: implications for therapy of peptic ulcer and reflux oesophagitis. ( Bium, AL, 1989)
"Due to its potent and long-lasting antisecretory properties is omeprazole, the first clinically used H+/K+-adenosine triphosphatase inhibitor, highly effective in healing of duodenal and gastric ulcers and reflux oesophagitis."	4.77	H+/K+-adenosine triphosphatase inhibitors. A new approach to the treatment of acid-peptic diseases. ( Lamers, CB, 1989)
"Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus."	3.77	Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992)
"There are different clinical responses to omeprazole treatment in Iranian patients with gastroesophageal reflux disease."	3.76	Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. ( Biramijamal, F; Doughaiemoghaddam, M; Hossein-Nezhad, A; Pourshams, A; Sarie, H; Zendehdel, N, 2010)
"Omeprazole has given healing rates of 58-83% after treatment for 2 weeks and 84-100% after 4 weeks."	3.76	Clinical experience with omeprazole: assessment of efficacy and safety. ( Walan, A, 1989)
"Gastro-oesophageal reflux occurs when the pressure barrier of the lower oesophageal sphincter (LOS) fails due to a low basal pressure (less than or equal to 6 mm Hg), sphincteric relaxations or a noncompensated increase in intragastric pressure."	3.76	Pathophysiology and treatment of gastro-oesophageal reflux disease. ( Janssens, J; Vantrappen, G, 1989)
"Gastric ulcer patients (n=88) were assigned either to the group receiving Helicobacter pylori eradication treatment (54 patients) or to the control group (34 patients; omeprazole treatment for 4 weeks) and were followed up for 1-year or until gastric ulcer relapsed."	3.74	Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupcinskas, L, 2008)
" This study evaluated the inhibitory action of apigenin-7-O-beta-D-glucuronopyranoside (AGC), apigenin, and omeprazole on reflux oesophagitis and gastritis in rats."	3.73	The effects of apigenin-7-O-beta-D-glucuronopyranoside on reflux oesophagitis and gastritis in rats. ( Bai, KL; Choi, HJ; Ham, I; Jeong, JH; Min, YS; Park, SY; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2005)
"This study evaluated the inhibitory action of luteolin-7-O-beta-D-glucuronopyranoside, luteolin which was isolated from Salix gilgiana leaves, and omeprazole on reflux esophagitis and gastritis in rats."	3.73	The effect of luteolin-7-O-beta-D-glucuronopyranoside on gastritis and esophagitis in rats. ( Bai, KL; Ham, I; Kim, JH; Lee, YJ; Min, YS; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2006)
"Multiple gastric polyps have been reported to occur in adults receiving omeprazole therapy."	3.71	Gastric polyps and nodules in children receiving long-term omeprazole therapy. ( Israel, DM; Pashankar, DS, 2002)
"In this randomized multicenter trial with a 5-year followup, we found antireflux surgery to be more effective than omeprazole in controlling gastroesophageal reflux disease as measured by the treatment failure rates."	3.71	Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. ( Carlsson, J; Hatlebakk, JG; Julkonen, R; Lamm, M; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Pedersen, SA; Wiklund, I, 2001)
"Omeprazole is an effective long-term drug for gastroesophageal reflux disease after failed fundoplication in children."	3.71	Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. ( Blair, GK; Israel, DM; Pashankar, D, 2001)
" The first compares primary coronary angioplasty with streptokinase in the treatment of acute myocardial infarction, in the second trial, lansoprazole is compared with omeprazole in the treatment of reflux oesophagitis."	3.70	Sample size calculation in economic evaluations. ( Al, MJ; Michel, BC; Rutten, FF; van Hout, BA, 1998)
" A further evaluation was undertaken in patients with symptoms suggestive of GERD and in patients with non-ulcer dyspepsia, to identify factors that might predict symptom relief during treatment with omeprazole."	3.70	The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. ( Bolling-Sternevald, E; Carlsson, R; Dent, J; Johnsson, F; Junghard, O; Lauritsen, K; Lundell, L; Riley, S, 1998)
"Omeprazole has been used with increasing frequency for the treatment of conditions such as reflux oesophagitis, peptic ulcer disease, and Zollinger-Ellison syndrome."	3.70	Omeprazole and the development of acute hepatitis. ( Koury, SI; La Charité, DD; Stone, CK, 1998)
" pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study."	3.70	Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999)
"These findings indicate that (1) peptic esophagitis was a common cause of chronic abdominal pain in pediatric patients and (2) omeprazole was effective in the treatment of esophagitis in children and adolescents that was resistant to high-dose histamine2-receptor antagonists."	3.69	Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. ( Kane, R; Karjoo, M, 1995)
"In a previous study we reported lack of improvement in oesophageal motor function after complete healing of oesophagitis achieved by treatment with omeprazole for a median duration of 12 weeks."	3.69	Prolonged remission of oesophagitis does not alter the magnitude of oesophageal acid exposure. ( Colin-Jones, DG; Singh, P; Taylor, RH, 1994)
"A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole."	3.69	Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997)
" Hyperpepsinogenaemia A has been shown in patients with duodenal ulcer disease, Zollinger-Ellison syndrome, hypertrophic gastropathy, chronic renal failure, and during omeprazole treatment."	3.68	Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A. ( Biemond, I; Jansen, JB; Kreuning, J; Lamers, CB, 1993)
" Serum gastrin levels, non-antral gastric endocrine (argyrophil) cell growth, and the severity and type of concomitant gastritis were monitored in 66 unoperated and 8 antrectomized patients with poorly responsive peptic ulcer or reflux oesophagitis during up to 5 years' treatment with high-dose omeprazole, 40 mg daily."	3.68	Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. ( Creutzfeldt, W; Lamberts, R, 1992)
"A total of 143 patients with peptic ulceration of the duodenum, stomach and oesophagus who did not respond to 3 or more months of high-dose treatment with ranitidine, 450 mg or more daily, were treated with oral omeprazole, 40 mg daily."	3.68	Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. ( Brunner, GH; Creutzfeldt, W; Lamberts, R, 1990)
" To investigate the effect of omeprazole and higher-than-presently-recommended doses of H2-blockers, we evaluated gastric acidity and gastroesophageal reflux in 17 patients with severe-moderate esophagitis before and after treatment with 300 mg ranitidine twice daily or 20 mg omeprazole once daily."	3.68	Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. ( Fiorucci, S; Morelli, A; Santucci, L, 1990)
"Prevalence of newly identified Barrett's esophagus was 14 % with half diagnosed only after treatment."	2.80	Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing. ( Achem, SR; Adamson, SC; Alexander, JA; Arora, AS; Crowell, MD; Dabade, TS; DeJesus, RS; Diehl, NN; Enders, FT; Francis, DL; Fredericksen, M; Geno, DM; Houston, MS; Jung, KW; Katzka, DA; Lohse, M; Majka, AJ; Murray, JA; Namasivayam, V; O'Neil, AE; Orbelo, DM; Romero, Y, 2015)
"Lafutidine was non-inferior to famotidine in healing of reflux esophagitis."	2.80	Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. ( Chang, YW; Choi, MG; Chun, HJ; Han, SW; Jeong, HY; Jung, HC; Jung, HY; Jung, JT; Kim, EH; Kim, HS; Kim, HY; Kim, JG; Lee, DH; Lee, OJ; Lee, ST; Lee, SW; Lee, YC; Park, JJ; Park, SH; Seol, SY; Youn, SJ, 2015)
" Drug-related adverse events tended to be mild but were reported at rates of 9."	2.78	[Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-]. ( Kasugai, K; Kinoshita, Y; Miwa, H, 2013)
"Omeprazole was superior to famotidine for treatment of upper abdominal symptoms in patients with reflux esophagitis, which suggested that gastric acid might be a cause not only of reflux symptoms, but also of ulcer symptoms and dysmotility symptoms such as epigastric pain and feeling of fullness in reflux esophagitis."	2.74	Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. ( Adachi, K; Fujimoto, K; Fujimura, Y; Fujisawa, T; Fuyuno, S; Haruma, K; Hori, K; Kido, S; Kin, Y; Kinoshita, Y; Kobori, M; Kusaka, M; Kusunoki, H; Matsunobu, A; Miwa, H; Nakamura, Y; Ono, N; Oza, N; Sugimoto, K; Tano, N; Tomita, T; Watanabe, Y; Yamauchi, R; Yuki, M, 2009)
"Gastroesophageal reflux disease (GERD) is a common disorder."	2.73	Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment. ( Lin, SR; Xue, Y; Zhou, LY, 2008)
"Relapse was defined as the recurrence of macroscopic esophageal lesions."	2.73	Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? ( Boccia, G; Buonavolontà, R; Manguso, F; Miele, E; Staiano, A, 2007)
"Rabeprazole is an effective and well-tolerated drug for GERD treatment."	2.72	[A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis]. ( Baek, JT; Chung, IK; Jeong, HY; Kim, AN; Kim, SH; Kim, SJ; Lee, BS; Lee, DS; Lee, GS; Lee, JM; Lee, SH; Lee, TY; Nam, SW; Oh, JI; Shin, JE; Sung, JK; Yoon, SJ, 2006)
"Pantoprazole was safe and well tolerated."	2.71	Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. ( Delgado, J; Dibildox, M; Gonzalez, J; Madrazo-de la Garza, A; Vargas, A; Yañez, P, 2003)
"Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being."	2.71	Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003)
" In addition, L-OMP is advantageous in its once-a-day dosing and might be an alternative to S-H2RA, especially in Korean patients with MMRE."	2.71	[Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis]. ( Baik, SK; Cho, MY; Kim, HS; Kim, JM; Kim, JW; Kwon, SO; Lee, DK; Suk, KT, 2004)
"Reflux esophagitis is a recurring condition for which many patients require maintenance therapy."	2.71	[A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study]. ( Han, SY; Jee, SR; Kim, DH; Lee, JT; Park, SJ; Seol, SY; Urm, SH, 2005)
"Esomeprazole 40 mg is an effective and safe drug at least comparable to omeprazole in treating Chinese EE patients."	2.71	Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. ( Chang, FY; Chen, CY; Lai, YL; Lee, SD; Lu, CL; Luo, JC, 2005)
"A total of 119 Japanese patients with recurrent reflux oesophagitis underwent cytochrome P450 2C19 genotyping prior to receiving daily omeprazole 10 mg or 20 mg for 6-12 months, during which adverse event frequency, serum gastrin levels and endoscopic findings were monitored."	2.71	Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. ( Aoyama, N; Arakawa, T; Chida, N; Fujimoto, K; Hamada, S; Hoshino, E; Inoue, M; Kawahara, Y; Konda, Y; Maekawa, T; Mine, T; Mitachi, Y; Nagai, T; Nakajima, M; Ohkusa, T; Sato, N; Seno, H; Shimatani, T; Tadokoro, K; Yoshida, N, 2005)
"Both rabeprazole doses were significantly superior to placebo in preventing relapse of heartburn frequency and improving patient quality of life."	2.71	Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005)
" This study was designed to investigate the dosing patterns of patients on on-demand treatment and to compare lansoprazole with omeprazole in this regard."	2.70	On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. ( Grove, O; Johnsson, F; Moum, B; Simren, M; Thoring, M; Vilien, M, 2002)
"Pantoprazole once daily was superior to nizatidine b."	2.70	Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2001)
" No drug related severe adverse event was reported."	2.70	[Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002]. ( Azerad, MA; Fassotte, C; Penson, J; Puttemans, M, 2001)
"For the long term maintenance treatment of reflux esophagitis several strategies have been proposed with the aim of reducing the daily dosage or the frequency of drug administration."	2.70	Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. ( Baldi, F; Cappiello, R; Ghersi, S; Morselli-Labate, AM, 2002)
"Lansoprazole was also significantly superior to placebo in relieving symptoms in patients with reflux esophagitis."	2.69	A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. ( Dorsch, E; Earnest, DL; Greski-Rose, PA; Jennings, DE; Jones, J, 1998)
"Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion."	2.69	Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. ( Eloff, FP; Fischer, R; Grundling, HD; Honiball, PJ; Louw, JA; Simjee, AE; Spies, SK; Theron, I; Van Rensburg, CJ; Van Zyl, JH, 1999)
"Lansoprazole or ranitidine was given to 133 patients for 4-8 weeks in a double-blind, randomized, parallel group, multicentre trial."	2.69	Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. ( Jansen, JB; Van Oene, JC, 1999)
"Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall."	2.69	Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000)
"Pantoprazole is a new proton pump inhibitor with a potent antisecretory activity, well defined pharmacokinetics and safety profile."	2.69	Pantoprazole versus omeprazole in the treatment of reflux esophagitis. ( Horvat, D; Ivandić, A; Jurisić-Orzen, D; Kotromanović, Z; Maksimović, Z; Males, J; Mandić, B; Nedić, P; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A; Vladika, I; Vranjes, Z, 1999)
"Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD."	2.69	Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. ( Beker, JA; Bjaaland, T; Dekkers, C; Finnegan, V; Humphries, TJ; Thjodleifsson, B, 2000)
"Esomeprazole 40 mg was also significantly more effective than omeprazole for healing at week 4 and for all secondary variables evaluating heartburn resolution."	2.69	Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. ( Collins, DW; D'Amico, D; Falk, GW; Hamelin, B; Joelsson, B; Johnson, DA; Kahrilas, PJ; Schmitt, C; Whipple, J, 2000)
" Pharmacokinetic study was optional for subjects and was performed in 25 of the 57 enrolled."	2.69	Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. ( Andersson, T; Becker, M; Behrens, R; Dalväg, A; Drouin, E; Göthberg, G; Hassall, E; Koletzko, S; Lundborg, P; Marcon, M; Martin, S; Radke, M; Shepherd, R, 2000)
"Omeprazole was significantly more effective than cisapride (P = 0."	2.68	A comparison of five maintenance therapies for reflux esophagitis. ( Badalamenti, S; Battaglia, G; Di Mario, F; Leandro, G; Mela, GS; Pantalena, M; Pilotto, A; Savarino, V; Termini, R; Vigneri, S, 1995)
"Lansoprazole is a H+."	2.68	Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. ( Bardhan, KD; Brocklebank, D; Hawkey, CJ; Long, RG; Morgan, AG; Moules, IK; Wormsley, KG, 1995)
"Pantoprazole is a new substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K(+)-ATPase."	2.68	A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. ( Herz, R; Hölscher, AH; Mössner, J; Schneider, A, 1995)
"Each omeprazole regimen was superior to placebo in preventing both symptomatic relapse (life table analysis, p < 0."	2.68	Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. ( Bate, CM; Booth, SN; Crowe, JP; Hepworth-Jones, B; Keeling, PW; Mountford, RA; Richardson, PD; Taylor, MD, 1995)
"Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity."	2.68	A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. ( Avner, D; Greski-Rose, PA; Jennings, DE; Jhala, N; Robinson, M; Sahba, B, 1995)
"Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms."	2.68	Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. ( Avner, D; Haber, M; Lanza, F; Robinson, M, 1996)
"Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+-ATPase."	2.68	Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. ( Bethke, TD; Botha, JF; Cariem, AK; Eloff, FP; Grundling, HD; Honiball, PJ; Marks, IN; Segal, I; Simjee, AE; Spies, SK; Theron, I; van Rensburg, CJ; van Zyl, JH, 1996)
"Pantoprazole is a new substituted benzimidazole which inhibits gastric H+,K(+)-ATPase."	2.68	Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. ( Belaïche, J; Colin, R; Corinaldesi, R; Geldof, H; Maier, C; Valentini, M, 1995)
"Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0."	2.68	Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997)
"Both omeprazole regimens were superior to placebo in preventing recurrence of symptoms (P < 0."	2.68	Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study. ( Behar, J; Berman, R; Dayal, Y; Hirschowitz, BI; Kranz, KR; Peterson, WL; Robinson, M; Roufail, W; Sabesin, SM; Simon, TJ; Sontag, SJ; Tarnawski, A; Wu, WC, 1997)
" In children, data on its use are limited, and problems about the dosage are unresolved."	2.68	Omeprazole for severe reflux esophagitis in children. ( Bawa, P; De Giacomo, C; Fiocca, R; Franceschi, M; Luinetti, O, 1997)
"Rabeprazole was well-tolerated in this short-term study."	2.68	Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. ( Greenwood, B; Humphries, TJ; Maton, PN; Robinson, M; Rodriguez, S, 1997)
"Relapses were re-treated with omeprazole 40 mg; upon rehealing, patients were put on maintenance omeprazole 20 mg daily for up to 4."	2.68	Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Manek, S; Morris, P; Parkin, S; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A, 1997)
"Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+."	2.68	One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. ( Koop, H; Maier, C; Mössner, J; Porst, H; Schneider, A; Wübbolding, H, 1997)
"Patients with reflux esophagitis have rapid relapses after treatment withdrawal."	2.67	Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. ( Carling, L; Edwin, B; Glise, H; Hallerbäck, B; Havu, N; Lundberg, K; Lyrenäs, E; Unge, P, 1994)
"Lansoprazole was significantly more effective than ranitidine for relief of heartburn and reduction of antacid tablet use."	2.67	Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. ( Feldman, M; Fisher, RS; Greski-Rose, PA; Harford, WV; Jennings, DE; Murray, SB; Sampliner, RE, 1993)
" No significant pathological findings were noted, and no adverse events were attributable to the study treatments."	2.67	Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. ( Dent, J; Hetzel, DJ; Mackinnon, M; Narielvala, FM; Reed, W; Shearman, DJ; Solcia, E; Yeomans, ND, 1994)
", demonstrating the existence of a dose-response relationship for omeprazole."	2.67	Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? ( Bate, CM; Booth, SN; Crowe, JP; Hepworth-Jones, B; Richardson, PD; Taylor, MD, 1993)
"Lansoprazole was found to be an effective and safe alternative to omeprazole in short-term treatment of moderate reflux oesophagitis."	2.67	Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. ( Berstad, A; Carling, L; Ekström, P; Halvorsen, L; Hatlebakk, JG; Hovdenak, N; Stallemo, A; Svedberg, LE; Trondstad, R; Unge, P, 1993)
" In conclusion, omeprazole was far superior to ranitidine in preventing recurrence, a goal achieved without adverse events and significant abnormalities in the oxyntic mucosal exocrine or endocrine cells but with a moderate increase in basal gastrin levels."	2.67	Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. ( Backman, L; Ekström, P; Enander, LK; Falkmer, S; Fausa, O; Grimelius, L; Havu, N; Lind, T; Lönroth, H; Lundell, L, 1991)
" This therapeutic advantage was achieved without adverse events and without significant abnormalities in the endocrine or exocrine cell population of the oxyntic mucosa."	2.67	Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. ( Lundell, L, 1990)
"100) treated with omeprazole and 31 of 69 patients (45 p."	2.66	[Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium]. ( Barbier, P; Carlsson, R; Eriksson, S; Isal, JP; Rampal, P; Zeitoun, P, 1989)
" The incidence of serious adverse events reported in comparative short-term studies with H2-receptor antagonists and placebo were similar."	2.66	The clinical safety of omeprazole. ( Sölvell, L, 1989)
"Omeprazole is a highly effective treatment for erosive/ulcerative peptic oesophagitis, 40 mg daily being marginally superior to 20 mg."	2.66	Evaluation of omeprazole in reflux oesophagitis. ( Dent, J; Hetzel, DJ; MacKinnon, MA; Narielvala, FM; Reed, WD, 1989)
"Omeprazole is a substituted benzimidazole which inhibits profoundly and long-lasting human acid secretion."	2.66	[Omeprazole in the therapy of acid-induced diseases]. ( Dammann, HG; Müller, P; Simon, B, 1987)
"Omeprazole is a highly effective treatment for peptic esophagitis."	2.66	Healing and relapse of severe peptic esophagitis after treatment with omeprazole. ( Beveridge, BR; Dent, J; Gibson, GG; Hetzel, DJ; Laurence, BH; Mackinnon, M; McCarthy, JH; Mitchell, B; Narielvala, FM; Reed, WD, 1988)
"Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD)."	2.53	The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. ( Chen, L; Chen, Y; Li, B, 2016)
"The treatment of Barrett's esophagus is controversial."	2.43	[The clinical strategy for the Barrett's esophagus]. ( Goto, H; Kitabatake, S; Niwa, Y, 2005)
"Whether these patients are part of the GERD spectrum or have another diagnosis is not clear."	2.43	Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006)
"Esomeprazole has an improved pharmacokinetic profile, resulting in increased systemic exposure and less interindividual variability compared with omeprazole, and more effective suppression of gastric acid production compared with other proton pump inhibitors."	2.42	Review of esomeprazole in the treatment of acid disorders. ( Johnson, DA, 2003)
" Multicentre randomised controlled studies are needed to better define the efficacy profile, the optimal dosage with respect to the different indications and the safety profile for chronic therapy of proton pump inhibitors in children."	2.42	Proton pump inhibitors in children: a review. ( Gerarduzzi, T; Marchetti, F; Ventura, A, 2003)
"Esomeprazole has FDA-approved labeling for use in the treatment of symptomatic gastroesophageal reflux disease (GERD), including healing and maintenance of healing of erosive esophagitis and as part of a triple-drug regimen for Helicobocter pylori infection."	2.41	Esomeprazole: a clinical review. ( Hedge, DD; Johnson, TJ, 2002)
" Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment."	2.41	Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. ( Trépanier, EF, 2000)
"Esomeprazole has significantly higher oral bioavailability than omeprazole, resulting in greater acid suppression."	2.41	Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy. ( Talley, NJ; Thitiphuree, S, 2000)
" Instances in which laparoscopic Nissen fundoplication should be considered include: 1) Individuals who are intolerant of proton pump inhibitor therapy because of side effects, 2) When patients are inadequately responsive to proton pump inhibitor therapy even after dosage and dose interval have been optimized, and 3) When a patient desires a permanent solution to their reflux problem that frees them of the need to chronically consume pharmaceuticals."	2.41	Management of GERD: medical versus surgical. ( Kahrilas, PJ, 2001)
"The base of the treatment of reflux esophagitis is the inhibition of the gastric acid secretion with proton pump inhibitors (PPI) or by H2-receptor antagonist."	2.41	[Long-term results of conservative management of reflux esophagitis]. ( Dorta, G; Viani, F, 2001)
"Esomeprazole is a new proton pump inhibitor, which has been compared to omeprazole for the treatment of reflux oesophagitis in clinical trials."	2.41	Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. ( Edwards, SJ; Lind, T; Lundell, L, 2001)
"Esomeprazole is a new PPI and is the S-isomer of racemic omeprazole."	2.41	Esomeprazole for acid peptic disorders. ( Kale-Pradhan, PB; Landry, HK; Sypula, WT, 2002)
" The bioavailability of lansoprazole is 85%; that of omeprazole is 54%."	2.39	Lansoprazole and omeprazole in the treatment of acid peptic disorders. ( Blum, RA, 1996)
"The vast majority of patients with GERD have mild symptoms, no gross endoscopic evidence of esophagitis, and little risk of developing complications."	2.39	Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. ( Reynolds, JC, 1996)
"Peptic esophageal strictures are a common sequelae of long-standing reflux esophagitis."	2.38	Peptic strictures of the esophagus. ( Marks, RD; Richter, JE, 1993)
"ECL-cell hyperplasia and carcinoids which occur during application of very high doses of omeprazole in rats are not caused by a direct effect of omeprazole."	2.38	[Risk for developing tumors in therapy with the proton pump inhibitor omeprazole]. ( Arnold, R; Eissele, R, 1993)
"Omeprazole, 20 mg daily, was found to be a highly effective maintenance therapy in patients with ulcerative oesophagitis, keeping 67-89% of patients in remission for 1 year, compared with 10-25% of patients treated with ranitidine, 150 mg twice daily."	2.38	Controlled clinical trials of omeprazole in the long-term management of reflux disease. ( Hetzel, DJ, 1992)
" Conventional dosing with H2-receptor antagonists has been successful in only about 50% of the patients with reflux esophagitis."	2.38	The role of omeprazole in healing and prevention of reflux disease. ( Klinkenberg-Knol, EC, 1992)
"Omeprazole is a potent, highly specific, and clinically efficacious anti-secretory agent."	2.38	Experience with omeprazole in erosive oesophagitis. ( Decktor, DL; Robinson, MG, 1991)
" Post-evening meal (PEM) dosing of H2-receptor antagonists appears to be a rational method of suppressing late evening gastric acidity, but on balance the symptomatic response of twice daily dosing is superior to once daily dosing."	2.38	Reflux esophagitis. ( Nio, CY; Schotborgh, RH; Tytgat, GN, 1990)
"Omeprazole has been shown to provide more rapid symptom relief and to heal ulcers more quickly and reliably than H2-receptor antagonists in duodenal ulcer, gastric ulcer and reflux oesophagitis."	2.38	Clinical development programme for omeprazole. ( Walan, A, 1990)
" Dinnertime dosing of cimetidine appears to be a rational method of suppressing late-evening gastric acidity."	2.38	Drug therapy of reflux oesophagitis: an update. ( Tytgat, GN, 1989)
"Omeprazole has been shown to give significantly higher healing rates than ranitidine or cimetidine in patients with duodenal ulcer and gastric ulcer."	2.38	Clinical utility and safety of omeprazole. ( Walan, A, 1989)
"Acid reflux esophagitis was induced by ligating the transitional region between the forestomach and the glandular portion and then wrapping the duodenum near the pylorus."	1.40	Acid reflux directly causes sleep disturbances in rat with chronic esophagitis. ( Arakawa, T; Fujiwara, Y; Nakahara, K; Shiba, M; Tanigawa, T; Tominaga, K; Tsukahara, T; Urade, Y; Watanabe, T; Yamagami, H, 2014)
"Although most patients with gastro-oesophageal reflux disease (GERD) benefit from proton pump inhibitor (PPI) therapy, some experience only partial symptom relief."	1.38	Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. ( Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B, 2012)
"nonwhite patients with gastro-oesophageal reflux disease (GERD)."	1.37	Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors. ( Illueca, M; Johnson, DA; Monyak, JT; Sharma, P, 2011)
"The correlation between gastroesophageal reflux and several related variables was evaluated."	1.35	Gastroesophageal scintigraphy in the evaluation of adult patients with chronic cough due to gastroesophageal reflux disease. ( Cerci, SS; Oztürk, O; Sahin, U; Senol, A; Songür, N; Songür, Y; Yarktaş, MH, 2008)
"Omeprazole was administered to the oesophagitis rats for 10 days."	1.35	Experimental oesophagitis in the rat is associated with decreased voluntary movement. ( Iizuka, S; Koseki, J; Matsumoto, T; Miwa, H; Oshima, T; Sakurai, J; Tomita, T, 2009)
"It was shown that gastroesophageal reflux disease was one of the possible causes of eosinophilia."	1.34	[A case of gastroesophageal reflux disease with marked eosinophilia]. ( Inoue, T; Inui, Y; Katata, T; Kizu, T; Kohro, T; Matsumoto, Y; Miyoshi, R; Nishikawa, M; Watanabe, C; Yasunaga, Y, 2007)
"Pantoprazole is an irreversible proton pump inhibitor that is administered as a racemic mixture clinically."	1.33	Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs. ( Cao, H; Hu, ZQ; Ikejima, T; Sun, LX; Wang, MW; Zhao, WH, 2005)
"The scale of GERD-HRQL decreased significantly in RE patients than in NERD patients."	1.33	[The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease]. ( Hou, XH; Ke, MY; Liu, XH; Luo, JY; Song, ZQ; Sun, J; Yuan, YZ; Zha, H; Zhu, YL, 2005)
"Fundic gland polyps have been described either in association with genetic polyposis syndromes of the colon, or in a sporadic form."	1.33	Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. ( Bellone, S; Caruso, S; Declich, P; Ferrara, A; Tavani, E, 2005)
"Omeprazole is a proton pump inhibitor which reduces both basal and stimulated gastric acid secretion by inhibiting the parietal cell enzyme H(+)-K(+)-adenosine triphosphatase."	1.33	[Anaphylaxis caused by omeprazole]. ( Bauer, C; Fackler, I; Kamann, S; Przybilla, B, 2006)
"Cough was significantly less severe in NEE adolescents than in younger children."	1.33	Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006)
"Presence of gastro-oesophageal reflux symptoms and medication of proton pump inhibitors, H2-blockers or prokinetics were investigated at final endoscopy."	1.32	Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. ( Chayama, K; Haruma, K; Manabe, N; Sasaki, A; Tanaka, S; Yoshihara, M, 2003)
"Gastroesophageal reflux disease (GERD) has evolved from a scarcely reported, little understood disease process just a century ago to a now highly prevalent disease with up to 25% of the population complaining of symptoms of reflux."	1.32	GERD 2003: issues from the past and a consensus for the future. ( Kidd, M; Modlin, I, 2004)
"Both acid and bile reflux is significantly suppressed by proton pump inhibitor therapy with exceptions among individual esophagitis patients."	1.31	Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. ( Menges, M; Müller, M; Zeitz, M, 2001)
" Although most clinical studies on long-term treatment with omeprazole or other proton pump inhibitors do not report serious adverse effects, the issue of prolonged hypergastrinemia and tissue growth is unsettled, and many clinicians are reluctant to recommend long-term use of omeprazole or of other proton pump inhibitors."	1.31	Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. ( Friedlander, Y; Ligumsky, M; Lysy, J; Siguencia, G, 2001)
"Gastroesophageal reflux disease has a multifactorial etiology."	1.31	Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. ( Gadenstaetter, M; Klaus, A; Klingler, PJ; Obrist, P; Profanter, C; Weiss, H; Wetscher, GJ; Wykypiel, H, 2001)
"The other two approaches prevent more recurrences: waiting to initiate maintenance therapy until symptoms recur once requires an additional $73 for each recurrence prevented whereas maintenance PPI from the outset requires an additional $819 for each recurrence prevented."	1.30	Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. ( Harris, RA; Kuppermann, M; Richter, JE, 1997)
"The therapeutic approach to gastroesophageal reflux disease (GERD) in intellectually disabled individuals has not been studied extensively."	1.30	Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. ( Bohmer, CJ; Devillé, WL; Klinkenberg-Knol, EC; Meuwissen, SG; Niezen-de Boer, MC; Tuynman, HA; Voskuil, JH, 1997)
"If patients experience a symptomatic recurrence on the H2RA strategies, they then receive PPI maintenance."	1.30	Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. ( Harris, RA; Kuppermann, M; Richter, JE, 1997)
"The laryngitis was clinically and endoscopically unchanged in ten of the twelve (83."	1.30	[Is chronic laryngitis associated with Helicobacter pylori? Results of a prospective study]. ( Arps, H; Diehl, KL; Draf, W; Jaspersen, D; Kind, M; Weber, R, 1998)
"Treatment of gastroesophageal reflux disease (GERD) with modern acid-suppressive agents is supposed to be effective and safe."	1.30	Gastroesophageal reflux disease as a cause of death: analysis of fatal cases under conservative treatment. ( Rantanen, TK; Salo, JA, 1999)
"Within both the patient and volunteers groups, there were no significant differences between day 1 and day 7 in any of the pharmacokinetic parameters including maximum concentration (Cmax), area under the concentration-time curve (AUC), and terminal half-life of elimination (t(1/2))."	1.30	Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ( Barclay, ML; Begg, EJ; Ketelbey, JW; Peters, WA; Robson, RA, 1999)
"Therefore, we diagnosed bronchial asthma associated with reflux esophagitis and gastroduodenal ulcer."	1.29	[A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride]. ( Arakawa, M; Fujimori, K; Suzuki, E, 1994)
"In patients with systemic sclerosis peristaltic abnormalities may delay gastric emptying, giving rise to bacterial overgrowth, including possibly Helicobacter pylori (HP)."	1.29	Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication. ( Goerz, G; Humfeld, S; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1994)
"Omeprazole is a powerful inhibitor of gastric acid and may suppress Helicobacter pylori by effecting the pKa of H pylori urease, by altering the pattern of infection, or by promoting overgrowth of other bacteria."	1.29	Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. ( Baron, JH; Gummett, PA; Karim, QN; Logan, RP; Misiewicz, JJ; Walker, MM, 1995)
" Moreover, if omeprazole is administered at a pharmacologically effective dosage for a short period of time, it may not have serious effects on the ultrastructure of human parietal cells."	1.29	The effects of omeprazole on the ultrastructure of gastric parietal cells. ( Fujii, T; Kato, S; Naganuma, H; Nakagawa, H; Nakano, K, 1994)
"Treatment of omeprazole induces profound inhibition of gastric acid secretion, resulting in hypergastrinaemia."	1.29	Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole. ( Biemond, I; Jansen, JB; Kuijpers, IJ; Lamers, CB; Meijer, JL, 1994)
"Omeprazole is an antagonist to the H+K+ ATPase of the gastric parietal cell."	1.29	Electrolyte disturbance with omeprazole therapy. ( Matthew, D; Melville, C; Milla, P; Shah, A, 1994)
"The cervical site of dysphagia demonstrated acid-induced hypersensitivity to esophageal distension with water or air."	1.29	Unusual presentation of mucosal hypersensitivity secondary to gastroesophageal reflux disease. ( Andres, JM; Baron, TH; Richter, JE; Singh, S; Tennyson, GS, 1993)
"Between 1965 and 1990 200 patients were treated for peptic esophageal stricture by surgery or bougienage with antisecretory medication."	1.29	Peptic esophageal stricture: is surgery still necessary? ( Bischof, G; Feil, W; Riegler, M; Schiessel, R; Wenzl, E, 1996)
"A 46-year-old man with achalasia-like syndrome developed CREST syndrome 4 years later."	1.29	Achalasia-like syndrome as the first manifestation in a patient with CREST syndrome. ( Berenguer, J; Gálvez, C; Garrigues, V; Ponce, J; Valverde, J, 1996)
"Omeprazole has a potent antisecretory effect and is a suitable alternative for short-term treatment of refractory acid-related diseases; a relatively low dose (0."	1.29	Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. ( Chiba, H; Ebina, K; Fujii, K; Kato, S; Nakagawa, H, 1996)
"3%) had received previous therapy with H2-receptor antagonists and in 33% of these patients it was at an inadequate dose or for an inadequate period of dosing or both."	1.28	A drug usage review of omeprazole. ( Kay, EA; McManus, PV; Norris, CM; Petty, D, 1992)
" Successful control of reflux disease in these patients was achieved by increasing omeprazole therapy to a regime and dosage that achieved elevation of intragastric pH above 4 throughout the 24-hour period."	1.28	Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy. ( Klinkenberg-Knol, EC; Meuwissen, SG, 1992)
"Chronic atrophic gastritis was found in 45 (10."	1.28	Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. ( Carlsson, R; Dalväg, A; Fiocca, R; Havu, N; Solcia, E, 1992)
"Omeprazole is a new hydrogen-potassium adenosine triphosphatase antagonist with indications for severe reflux esophagitis and Zollinger-Ellison syndrome."	1.28	Fulminant hepatic failure related to omeprazole. ( Brogan, M; Cook-Glenn, C; Greenson, J; Jochem, V; Kirkpatrick, R; Sturgis, T, 1992)
"No further recurrence with 20 mg omeprazole was found later than six months."	1.28	Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. ( Arnold, R; Koop, H, 1991)
"The hydroxyproline concentration was significantly increased (P less than 0."	1.28	Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis. ( Hendel, L, 1991)
"However, reflux esophagitis is less well recognized."	1.28	Reflux esophagitis in patients with Zollinger-Ellison syndrome. ( Frucht, H; Gardner, JD; Jensen, RT; Maton, PN; Miller, LS; Vinayek, R, 1990)
"Fourteen of 24 patients (58%) had recurrence of endoscopic esophagitis documented between 26 and 300 days from the time of starting maintenance therapy."	1.28	Omeprazole in H2 receptor antagonist-resistant reflux esophagitis. ( Beck, IT; Da Costa, LR; Marciano-D'Amore, DA; Paterson, WG, 1990)
"Consequently, there was a fast recurrence of aggravation of reflux symptoms and oesophagitis."	1.28	Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. ( Jansen, JB; Klinkenberg-Knol, EC; Lamers, CB; Meuwissen, SG; Nelis, F, 1990)
"In patients with Barrett's esophagus, LES pressure was considerably lower and percentage exposure to acid was considerably higher than in either patients with esophagitis or controls (p less than 0."	1.28	Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. ( Farroni, F; Fiorucci, S; Morelli, A; Pelli, MA; Santucci, L, 1989)
"Treatment with omeprazole also gave faster and more pronounced pain relief."	1.27	Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors. ( Walan, A, 1986)

Research

Studies (455)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Change in Quality of Life as Assessed by Short Form 36 Questionnaire, Administered at Baseline and 6 Weeks After Each Intervention

Timeframe	Studies, this research(%)	All Research%
pre-1990	45 (9.89)	18.7374
1990's	233 (51.21)	18.2507
2000's	153 (33.63)	29.6817
2010's	24 (5.27)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Sebastián Domingo, JJ	1
Li, MJ	1
Li, Q	1
Sun, M	1
Liu, LQ	1
Zhang, W	1
Li, B	2
Sun, J	2
Wang, Z	1
Zhang, N	1
Shi, F	1
Pei, L	1
Kinoshita, Y	6
Miwa, H	5
Kasugai, K	2
Huo, X	2
Zhang, X	1
Yu, C	1
Zhang, Q	1
Cheng, E	1
Wang, DH	1
Pham, TH	2
Spechler, SJ	2
Souza, RF	2
Nagahara, A	1
Suzuki, T	1
Nagata, N	1
Sugai, N	1
Takeuchi, Y	1
Sakurai, K	1
Miyamoto, M	1
Inoue, K	1
Akiyama, J	1
Mabe, K	1
Konuma, I	1
Kamada, T	1
Haruma, K	3
Orbelo, DM	1
Enders, FT	1
Romero, Y	2
Francis, DL	1
Achem, SR	1
Dabade, TS	1
Crowell, MD	1
Geno, DM	1
DeJesus, RS	1
Namasivayam, V	1
Adamson, SC	1
Arora, AS	1
Majka, AJ	1
Alexander, JA	1
Murray, JA	2
Lohse, M	1
Diehl, NN	1
Fredericksen, M	1
Jung, KW	1
Houston, MS	1
O'Neil, AE	1
Katzka, DA	1
Kondo, T	1
Oshima, T	2
Koseki, J	2
Hattori, T	1
Kase, Y	1
Tomita, T	3
Fukui, H	1
Watari, J	1
Nakahara, K	1
Fujiwara, Y	1
Tsukahara, T	1
Yamagami, H	1
Tanigawa, T	1
Shiba, M	1
Tominaga, K	1
Watanabe, T	1
Urade, Y	1
Arakawa, T	2
Kim, EH	1
Lee, YC	1
Chang, YW	1
Park, JJ	1
Chun, HJ	1
Jung, HY	1
Kim, HS	2
Jeong, HY	2
Seol, SY	2
Han, SW	1
Choi, MG	1
Park, SH	1
Lee, OJ	1
Jung, JT	1
Lee, DH	1
Jung, HC	1
Lee, ST	1
Kim, JG	1
Youn, SJ	1
Kim, HY	1
Lee, SW	1
Tang, YP	1
Liu, SM	1
Wei, W	1
Wei, XD	1
Gong, YX	1
Wang, R	1
Li, SH	1
Liu, JW	1
Takeuchi, T	1
Oota, K	1
Harada, S	1
Edogawa, S	1
Kojima, Y	1
Sanomura, M	1
Sakaguchi, M	1
Hayashi, K	2
Hongoh, Y	1
Itabashi, T	1
Kitae, H	1
Hoshimoto, M	1
Takeuchi, N	1
Higuchi, K	1
Dunbar, KB	1
Agoston, AT	1
Odze, RD	1
Cipher, DJ	1
Castell, DO	3
Genta, RM	1
Chen, L	1
Chen, Y	1
Rao, CV	1
Vijayakumar, M	1
Xue, Y	2
Zhou, LY	2
Lin, SR	2
Songür, N	1
Songür, Y	1
Cerci, SS	1
Oztürk, O	1
Sahin, U	1
Senol, A	1
Yarktaş, MH	1
Sakurai, J	1
Matsumoto, T	1
Iizuka, S	1
Ishiyama, F	1
Iijima, K	2
Asanuma, K	1
Ara, N	1
Yoshitake, J	1
Abe, Y	1
Koike, T	2
Imatani, A	1
Ohara, S	2
Shimosegawa, T	2
Kusunoki, H	1
Kusaka, M	1
Kido, S	1
Yamauchi, R	1
Fujimura, Y	1
Watanabe, Y	2
Kobori, M	1
Kin, Y	1
Hori, K	1
Tano, N	1
Sugimoto, K	1
Nakamura, Y	1
Fujimoto, K	3
Oza, N	1
Matsunobu, A	1
Ono, N	1
Fuyuno, S	1
Adachi, K	3
Yuki, M	1
Fujisawa, T	1
Moretzsohn, LD	1
Carvalho, EB	1
Franco, JD	1
Soares, MP	1
Brito, EM	1
Belarmino, K	1
Coelho, LG	1
Broeders, JA	1
Draaisma, WA	1
Bredenoord, AJ	1
de Vries, DR	1
Rijnhart-de Jong, HG	1
Smout, AJ	2
Gooszen, HG	1
Hasosah, MY	1
Showail, M	1
Al-Sahafi, A	1
Satti, M	1
Jacobson, K	1
Morais, P	1
Baudrier, T	1
Mota, A	1
Cunha, AP	1
Cadinha, S	1
Barros, AM	1
Azevedo, F	1
Nam, SY	1
Choi, IJ	1
Ryu, KH	1
Kim, BC	1
Kim, CG	1
Nam, BH	1
Zendehdel, N	2
Biramijamal, F	1
Hossein-Nezhad, A	1
Sarie, H	1
Doughaiemoghaddam, M	1
Pourshams, A	1
Fernández-Fernández, FJ	1
Sesma, P	1
Caínzos-Romero, T	1
Ferreira, L	1
Yoshida, S	2
Nii, M	1
Date, M	1
Sharma, P	1
Johnson, DA	3
Monyak, JT	1
Illueca, M	1
Pace, F	3
Coudsy, B	1
DeLemos, B	1
Sun, Y	1
Xiang, J	1
LoCoco, J	1
Casalini, S	2
Li, H	1
Pelosini, I	1
Scarpignato, C	2
Bytzer, P	1
van Zanten, SV	1
Mattsson, H	1
Wernersson, B	1
Satoh, H	2
Schilling, D	1
Adamek, HE	1
Riemann, JF	1
Johnsson, F	2
Moum, B	1
Vilien, M	1
Grove, O	1
Simren, M	1
Thoring, M	1
Johnson, TJ	1
Hedge, DD	1
Kawano, S	1
Murata, H	1
Tsuji, S	1
Kubo, M	1
Tatsuta, M	1
Iishi, H	1
Kanda, T	1
Sato, T	1
Yoshihara, H	1
Masuda, E	1
Noguchi, M	2
Kashio, S	1
Ikeda, M	1
Kaneko, A	1
Romagnuolo, J	1
Meier, MA	1
Sadowski, DC	1
Mitsunaga, A	1
Matsumoto, R	1
Hoshino, Y	1
Nakamura, S	1
Murata, Y	1
Oi, I	1
Hayashi, N	1
Kovacs, TO	1
Wilcox, CM	1
DeVault, K	1
Miska, D	1
Bochenek, W	2
Pashankar, DS	1
Israel, DM	2
Osadchuk, MA	2
Lipatova, TE	2
Chaplygin, NV	2
Arutiunov, AG	1
Burkov, SG	1
Burdina, EG	1
Svirchev, VV	1
Leitner, A	1
Zöllner, P	1
Frazzoni, M	1
De Micheli, E	1
Grisendi, A	1
Savarino, V	2
Madrazo-de la Garza, A	1
Dibildox, M	1
Vargas, A	1
Delgado, J	1
Gonzalez, J	1
Yañez, P	1
Kawamura, M	1
Suzuki, J	1
Kayaba, S	1
Noguchi, K	1
Hamada, S	2
Yamamoto, T	1
Matsumoto, J	1
Kosaihira, T	1
Nomoto, M	1
Kitajima, S	1
Arima, T	1
Damiano, A	1
Siddique, R	1
Xu, X	1
Johanson, J	1
Sloan, S	2
Körner, T	2
Schütze, K	1
van Leendert, RJ	1
Fumagalli, I	2
Costa Neves, B	1
Bohuschke, M	1
Gatz, G	1
Pilotto, A	3
Leandro, G	3
Franceschi, M	5
Sasaki, A	1
Manabe, N	1
Tanaka, S	1
Yoshihara, M	1
Chayama, K	1
Moore, DJ	1
Tao, BS	1
Lines, DR	1
Hirte, C	1
Heddle, ML	1
Davidson, GP	1
Marchetti, F	1
Gerarduzzi, T	1
Ventura, A	1
Kao, AW	1
Sheu, BS	1
Sheu, MJ	1
Chang, YM	1
Huang, SF	1
Chuang, CH	1
Lai, YL	2
Kao, YH	1
Füessl, HS	2
Hashimoto, T	1
Hamamoto, N	1
Hirakawa, K	1
Niigaki, M	1
Miyake, T	1
Taniura, H	1
Ono, M	1
Kaji, T	1
Suetsugu, H	1
Yagi, J	1
Komazawa, Y	1
Mihara, T	1
Katsube, T	1
Fujishiro, H	1
Shizuku, T	1
Hattori, S	1
Yamamoto, S	1
Kuipers, EJ	8
Nelis, GF	3
Klinkenberg-Knol, EC	20
Snel, P	8
Goldfain, D	1
Kolkman, JJ	1
Festen, HP	10
Dent, J	8
Zeitoun, P	5
Havu, N	7
Lamm, M	2
Walan, A	8
Swiatkowski, M	1
Budzyński, J	1
Kłopocka, M	1
Grad, K	1
Pulkowski, G	1
Augustyńska, B	1
Suppan, K	1
Fabisiak, J	1
Junghard, O	6
Carlsson, R	8
Lind, T	8
Peitz, U	1
Raps, S	1
Plein, K	2
Leodolter, A	1
Hotz Dagger, J	1
Malfertheiner, P	2
Kim, JW	1
Lee, DK	1
Suk, KT	1
Kim, JM	2
Baik, SK	1
Kwon, SO	1
Cho, MY	1
Gillessen, A	3
Modlin, I	1
Kidd, M	1
Wang, CH	1
Wang, LX	1
Yang, Z	1
Chen, SQ	1
Zhu, H	1
Lu, YP	1
Härtter, S	1
Connemann, B	1
Schönfeldt-Lecuona, C	1
Sachse, J	1
Hiemke, C	1
Fiedorek, S	1
Tolia, V	1
Gold, BD	1
Huang, B	1
Stolle, J	1
Lee, C	1
Gremse, D	1
Calabrese, C	2
Fabbri, A	1
Bortolotti, M	1
Cenacchi, G	1
Carlo, S	1
Zahlane, D	1
Miglioli, M	2
Di Febo, G	1
Dohmen, W	2
Fuchs, W	3
Cornish, P	1
Calleja, JL	1
Suarez, M	1
De Tejada, AH	1
Navarro, A	1
Ott, EA	1
Mazzoleni, LE	1
Edelweiss, MI	1
Sander, GB	1
Wortmann, AC	1
Theil, AL	1
Somm, G	1
Cartell, A	1
Rivero, LF	1
Uchôa, DM	1
Francesconi, CF	1
Prolla, JC	1
Jee, SR	1
Kim, DH	2
Park, SJ	1
Han, SY	1
Urm, SH	1
Lee, JT	1
Chen, CY	1
Lu, CL	1
Luo, JC	1
Chang, FY	1
Lee, SD	1
Ohkusa, T	1
Maekawa, T	1
Nakajima, M	1
Hoshino, E	2
Mitachi, Y	1
Mine, T	1
Kawahara, Y	1
Nagai, T	1
Aoyama, N	1
Yoshida, N	1
Tadokoro, K	1
Chida, N	1
Konda, Y	1
Seno, H	1
Shimatani, T	1
Inoue, M	1
Sato, N	1
Min, YS	2
Yim, SH	2
Bai, KL	2
Choi, HJ	1
Jeong, JH	1
Song, HJ	2
Park, SY	1
Ham, I	2
Whang, WK	2
Sohn, UD	2
Cao, H	1
Wang, MW	1
Sun, LX	1
Ikejima, T	1
Hu, ZQ	1
Zhao, WH	1
Xu, JY	1
Xie, XP	1
Hou, XH	2
Annese, V	1
Prada, A	1
Zambelli, A	1
Nardini, P	1
Bianchi Porro, G	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis[NCT01733810]		12 participants (Actual)	Interventional	2013-02-01	Completed
Omepral® Tablets Mega-study to Investigate the Efficacy on Various Type of Acid Reflux Related Symptoms and QOL, and Epidemiology in Patients With Erosive Esophagitis in Daily Medical Practice[NCT00859287]		10,703 participants (Actual)	Observational	2007-06-30	Completed
Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534]	Phase 3	407 participants (Actual)	Interventional	2006-10-31	Completed
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788]	Phase 2/Phase 3	144 participants (Actual)	Interventional	2010-08-31	Completed
A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188]	Phase 1	24 participants (Actual)	Interventional	2021-06-24	Completed
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757]		48 participants (Anticipated)	Interventional	2012-03-31	Not yet recruiting
Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404]		98 participants (Actual)	Interventional	2009-03-01	Completed
Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study[NCT01574573]		52 participants (Actual)	Interventional	2009-06-30	Terminated (stopped due to Closed due to lack of recruitment)
Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study[NCT02706938]		65 participants (Actual)	Interventional	2016-04-08	Completed
Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study[NCT02476097]	Phase 4	58 participants (Anticipated)	Interventional	2015-06-30	Active, not recruiting
A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753]	Phase 4	143 participants (Actual)	Interventional	2014-01-31	Completed
Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488]	Phase 4	6 participants (Actual)	Interventional	2008-04-30	Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study)
Study of a Dietary Supplement for Reflux During Sleep[NCT02274636]		50 participants (Anticipated)	Interventional	2014-10-31	Not yet recruiting
A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265]	Phase 4	18 participants (Actual)	Interventional	2006-08-31	Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Secondary outcome will be assessed at baseline and 6 weeks after starting each period

Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention

Intervention	scores on a scale (Mean)
Head of Bed Elevation	6.5992
Control	-0.3139

Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant. (NCT02706938)
Timeframe: Primary outcome will be assessed at baseline and 6 weeks after starting each period

Patient Preference

Intervention	scores on a scale (Mean)
Head of Bed Elevation	-1.2397
Control	0.0869

Percentage of patients who preferred head of bed elevation after trial ending (NCT02706938)
Timeframe: Secondary outcome will be assessed 14 weeks after starting the trial

Article	Year
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine, 2017, Volume: 96, Issue:39 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole;	2017
The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Scientific reports, 2016, 09-01, Volume: 6 Topics: Anti-Ulcer Agents; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inh	2016
Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Current pharmaceutical design, 2013, Volume: 19, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Duodenal	2013
Esomeprazole: a clinical review. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002, Jul-15, Volume: 59, Issue:14 Topics: Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomepraz	2002
[Reflux esophagitis]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Esophagitis, Peptic; Gastritis, Atrophic;	2002
Review of esomeprazole in the treatment of acid disorders. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:2 Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis, Peptic; Gastric Acid	2003
[A case of gastric fundic polyps during long-term treatment of reflux esophagitis with omeprazole]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastric Fundus; Humans; Ome	2003
Proton pump inhibitors in children: a review. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003, Volume: 35, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, P	2003
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H	2005
[The clinical strategy for the Barrett's esophagus]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Ba	2005
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Alimentary pharmacology & therapeutics, 2006, Volume: 23 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys	2006
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Alimentary pharmacology & therapeutics, 2006, Sep-01, Volume: 24, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole;	2006
Gastroesophageal reflux disease symptoms on antisecretory therapy: acid, non-acid, or no GERD. Reviews in gastroenterological disorders, 2006,Summer, Volume: 6, Issue:3 Topics: Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Ma	2006
[Proton pump blockers and their significance in gastroenterology]. Vnitrni lekarstvi, 1995, Volume: 41, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas	1995
Esophageal tissue band transected with hot biopsy forceps. Digestive diseases and sciences, 1995, Volume: 40, Issue:10 Topics: Biopsy; Combined Modality Therapy; Deglutition Disorders; Dilatation; Esophagitis, Peptic; Esophagos	1995
Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. European journal of gastroenterology & hepatology, 1995, Volume: 7, Issue:5 Topics: Adult; Cimetidine; Double-Blind Method; Duodenal Ulcer; Esophagitis, Peptic; Female; Humans; Male; M	1995
[Lansoprazol]. Gastroenterologia y hepatologia, 1995, Volume: 18, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo	1995
Treatment of gastroesophageal reflux: the role of proton pump inhibitors. Advances in internal medicine, 1995, Volume: 40 Topics: Adult; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Male;	1995
[Therapy of reflux esophagitis]. Zeitschrift fur Gastroenterologie, 1993, Volume: 31 Suppl 5 Topics: Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Esophagitis, Peptic; Female; Gastric Acidit	1993
Reflux esophagitis in infants and children: a report from the Working Group on Gastro-Oesophageal Reflux Disease of the European Society of Paediatric Gastroenterology and Nutrition. Journal of pediatric gastroenterology and nutrition, 1994, Volume: 18, Issue:4 Topics: Biopsy; Child; Child, Preschool; Endoscopy; Epithelium; Esophagitis, Peptic; Histamine H2 Antagonist	1994
Refractory peptic lesions. Therapeutic strategies for ulcers and reflux esophagitis that resist standard regimens. Postgraduate medicine, 1993, Volume: 93, Issue:4 Topics: Anti-Ulcer Agents; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Drug Therapy, Com	1993
[Lansoprazole--profile of a new proton pump inhibitor]. Leber, Magen, Darm, 1994, Volume: 24, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A	1994
Peptic strictures of the esophagus. The American journal of gastroenterology, 1993, Volume: 88, Issue:8 Topics: Behavior Therapy; Causality; Cimetidine; Diagnosis, Differential; Dilatation; Esophageal Stenosis; E	1993
[Risk for developing tumors in therapy with the proton pump inhibitor omeprazole]. Versicherungsmedizin, 1993, Aug-01, Volume: 45, Issue:4 Topics: Animals; Carcinogenicity Tests; Carcinoid Tumor; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulc	1993
[Omeprazole. Its pharmacology and therapeutic efficacy]. Deutsche medizinische Wochenschrift (1946), 1993, Feb-19, Volume: 118, Issue:7 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison Syndrome	1993
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies. Alimentary pharmacology & therapeutics, 1993, Volume: 7 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis,	1993
Lansoprazole and omeprazole in the treatment of acid peptic disorders. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Jun-15, Volume: 53, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interacti	1996
The impact of omeprazole and laparoscopy upon hiatal hernia and reflux esophagitis. Journal of the American College of Surgeons, 1996, Volume: 183, Issue:4 Topics: Anti-Ulcer Agents; Esophagitis, Peptic; Fundoplication; Hernia, Hiatal; Humans; Laparoscopy; Omepraz	1996
The changing role of H2-receptor antagonists in acid-related diseases. European journal of gastroenterology & hepatology, 1996, Volume: 8 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic	1996
Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Nov-15, Volume: 53, Issue:22 Suppl 3 Topics: Aged; Anti-Ulcer Agents; Cisapride; Drug Interactions; Drug Therapy, Combination; Esophagitis, Pepti	1996
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 1997, Volume: 11 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lans	1997
Pantoprazole--a third proton pump inhibitor. Drug and therapeutics bulletin, 1997, Volume: 35, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Enzyme I	1997
Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis. PharmacoEconomics, 1993, Volume: 3, Issue:6 Topics: Cost-Benefit Analysis; Duodenal Ulcer; Economics, Pharmaceutical; Esophagitis, Peptic; Health Care C	1993
[Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Cost-Benefit Analysis; Enzyme Inhibitors; Esophag	2000
Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2000, Volume: 14 Suppl D Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis, Peptic; Gas	2000
Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy. International journal of clinical practice, 2000, Volume: 54, Issue:8 Topics: Adult; Aged; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Esomeprazole; Esophagitis	2000
Management of GERD: medical versus surgical. Seminars in gastrointestinal disease, 2001, Volume: 12, Issue:1 Topics: Adenocarcinoma; Anti-Ulcer Agents; Costs and Cost Analysis; Esophageal Neoplasms; Esophagitis, Pepti	2001
[Long-term results of conservative management of reflux esophagitis]. Therapeutische Umschau. Revue therapeutique, 2001, Volume: 58, Issue:3 Topics: Age Factors; Anti-Ulcer Agents; Diet; Drug Therapy, Combination; Esophagitis, Peptic; Helicobacter I	2001
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use]. La Revue du praticien, 2001, Apr-15, Volume: 51, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child	2001
A review of omeprazole use in the treatment of acid-related disorders in children. Clinical therapeutics, 2001, Volume: 23, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Child; Child, P	2001
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:11 Topics: Administration, Oral; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Esophagitis	2001
[Long-term therapy of gastrooesophageal reflux disease: Medical treatment or anti-reflux surgery?]. Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:12 Topics: Esophagitis, Peptic; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Humans; Multicenter	2001
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis,	2001
Esomeprazole for acid peptic disorders. The Annals of pharmacotherapy, 2002, Volume: 36, Issue:4 Topics: Absorption; Anti-Ulcer Agents; Clinical Trials as Topic; Esomeprazole; Esophagitis, Peptic; Humans;	2002
[Acute mucosal lesion of the upper-gastrointestinal tract observed after H. pylori-eradication]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: Acute Disease; Amoxicillin; Clarithromycin; Esophagitis, Peptic; Gastric Acid; Gastric Mucosa; Helic	2002
[Continuation of acid suppression therapy after H. pylori eradication]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme	2002
[Cause and prevention of nocturnal gastric acid breakthrough]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rh	2002
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs, 1992, Volume: 44, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer;	1992
[Omeprazole and maintenance treatment: new concepts for traditional therapies?]. Anales de medicina interna (Madrid, Spain : 1984), 1992, Volume: 9, Issue:9 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole	1992
Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion, 1992, Volume: 51 Suppl 1 Topics: Administration, Oral; Australia; Belgium; Biopsy; Double-Blind Method; Endoscopy, Gastrointestinal;	1992
Safety experience from long-term treatment with omeprazole. Digestion, 1992, Volume: 51 Suppl 1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cimetidine; Clinical Trials as Topic; Esophagitis, Pepti	1992
[Omeprazole]. Der Internist, 1992, Volume: 33, Issue:9 Topics: Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer	1992
Medical treatment of reflux esophagitis. Hepato-gastroenterology, 1992, Volume: 39, Issue:4 Topics: Esophagitis, Peptic; Follow-Up Studies; Gastrins; Humans; Omeprazole	1992
The role of omeprazole in healing and prevention of reflux disease. Hepato-gastroenterology, 1992, Volume: 39 Suppl 1 Topics: Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Recurrence; Time Fac	1992
Experience with omeprazole in erosive oesophagitis. Alimentary pharmacology & therapeutics, 1991, Volume: 5 Suppl 1 Topics: Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole	1991
[Conservative therapy of reflux esophagitis]. Zeitschrift fur Gastroenterologie. Verhandlungsband, 1990, Volume: 25 Topics: Cisapride; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Piperidines; Serotonin	1990
Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs, 1991, Volume: 42, Issue:1 Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Gastrointestinal Diseases; Histamine H2 Antagonists; H	1991
The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterology clinics of North America, 1990, Volume: 19, Issue:3 Topics: Antacids; Esophagitis, Peptic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole	1990
Reflux esophagitis. Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 175 Topics: Anti-Ulcer Agents; Cisapride; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Pip	1990
Clinical development programme for omeprazole. Digestion, 1990, Volume: 47 Suppl 1 Topics: Drug Administration Schedule; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer He	1990
Omeprazole: blocks gastric acid secretion completely. Drug and therapeutics bulletin, 1990, Jun-25, Volume: 28, Issue:13 Topics: Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Peptic Ulcer	1990
[Omeprazole. A new substance for inhibiting acid production]. Medizinische Monatsschrift fur Pharmazeuten, 1990, Volume: 13, Issue:2 Topics: Animals; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Zollinger-Ellison Synd	1990
Clinical experience with omeprazole: assessment of efficacy and safety. Journal of gastroenterology and hepatology, 1989, Volume: 4 Suppl 2 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli	1989
Pathophysiology and treatment of gastro-oesophageal reflux disease. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 165 Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio	1989
The clinical utility and safety of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic;	1989
Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Esophagitis, Peptic; Gastric Acid; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; O	1989
Treatment of reflux oesophagitis resistant to H2-receptor antagonists. Digestion, 1989, Volume: 44 Suppl 1 Topics: Drug Administration Schedule; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Rec	1989
Drug therapy of reflux oesophagitis: an update. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 168 Topics: Antacids; Bethanechol; Bethanechol Compounds; Cisapride; Domperidone; Esophagitis, Peptic; Histamine	1989
Clinical utility and safety of omeprazole. Methods and findings in experimental and clinical pharmacology, 1989, Volume: 11 Suppl 1 Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zolli	1989
Is there a need for strong gastric acid inhibition in clinical practice? Digestion, 1989, Volume: 44 Suppl 1 Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazo	1989
Omeprazole in the short-term treatment of reflux oesophagitis. Digestion, 1989, Volume: 44 Suppl 1 Topics: Drug Administration Schedule; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Ulcer	1989
Omeprazole: implications for therapy of peptic ulcer and reflux oesophagitis. Digestion, 1989, Volume: 44 Suppl 1 Topics: Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer	1989
H+/K+-adenosine triphosphatase inhibitors. A new approach to the treatment of acid-peptic diseases. Digestion, 1989, Volume: 44 Suppl 1 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer	1989
[Reflux esophagitis: therapeutic indications]. La Revue du praticien, 1988, Feb-04, Volume: 38, Issue:4 Topics: Cisapride; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Omeprazole; Piperidines	1988
The medical therapy of reflux oesophagitis. Bailliere's clinical gastroenterology, 1987, Volume: 1, Issue:4 Topics: Antacids; Bethanechol; Bethanechol Compounds; Cimetidine; Cisapride; Domperidone; Esophagitis, Pepti	1987
Omeprazole. Bailliere's clinical gastroenterology, 1988, Volume: 2, Issue:3 Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Sto	1988
[Omeprazole]. Gastroenterologie clinique et biologique, 1987, Volume: 11, Issue:11 Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esophagit	1987

Article	Year
[Therapeutic effects of the integrated acupuncture and Chinese herbal medicine on reflux esophagitis]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2017, Jul-12, Volume: 37, Issue:7 Topics: Acupuncture Points; Acupuncture Therapy; Anti-Ulcer Agents; Combined Modality Therapy; Drugs, Chines	2017
[Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:8 Topics: Aged; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Ome	2013
A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis. Journal of gastroenterology, 2014, Volume: 49, Issue:12 Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Esophagitis, Peptic; Female; Humans; Japan; Male; Middle Aged	2014
Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing. Digestive diseases and sciences, 2015, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Comorbidity; Drug Combinations; Endoscopy, Digest	2015
Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Digestive diseases and sciences, 2015, Volume: 60, Issue:6 Topics: Acetamides; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy;	2015
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy? Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anxiety; Cytochrome P-450 CYP2C19; Depression; Dos	2015
Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment. Chinese medical journal, 2008, Jul-20, Volume: 121, Issue:14 Topics: Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Esophagitis, Peptic; Extracellular Space; Female	2008
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. Journal of gastroenterology, 2009, Volume: 44, Issue:4 Topics: Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Histamine H2 Antagonists; H	2009
Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2009,Winter, Volume: 16, Issue:1 Topics: Adult; Aged; Brazil; Chemistry, Pharmaceutical; Drug Compounding; Esophageal pH Monitoring; Esophagi	2009
Effects of omeprazole on symptoms and quality of life in Japanese patients with reflux esophagitis: final results of OMAREE, a large-scale clinical experience investigation. BMC gastroenterology, 2011, Feb-28, Volume: 11 Topics: Adult; Aged; Anti-Ulcer Agents; Drug-Related Side Effects and Adverse Reactions; Esophagitis, Peptic	2011
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P	2011
[Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:2 Topics: Aged; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Ome	2013
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scandinavian journal of gastroenterology, 2002, Volume: 37, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and	2002
Randomized comparative study of omeprazole and famotidine in reflux esophagitis. Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:9 Topics: Aged; Drug Evaluation; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Ga	2002
Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon	2002
[Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2002, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; Epithel	2002
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh	2003
Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. Journal of pediatric gastroenterology and nutrition, 2003, Volume: 36, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Ulcer Agents; Benzim	2003
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Alimentary pharmacology & therapeutics, 2003, Apr-01, Volume: 17, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Esophagi	2003
Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Digestive diseases and sciences, 2003, Volume: 48, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Esophagitis, Pe	2003
Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion, 2003, Volume: 67, Issue:1-2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Confidence Intervals; Do	2003
Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Alimentary pharmacology & therapeutics, 2003, Jun-01, Volume: 17, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Metho	2003
Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. The Journal of pediatrics, 2003, Volume: 143, Issue:2 Topics: Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesoph	2003
On-demand therapy for Los Angeles grade A and B reflux esophagitis: esomeprazole versus omeprazole. Journal of the Formosan Medical Association = Taiwan yi zhi, 2003, Volume: 102, Issue:9 Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Female; Humans;	2003
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. Journal of gastroenterology and hepatology, 2003, Volume: 18, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid	2003
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disease Progression; Double-	2004
The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis. Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept	2004
Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scandinavian journal of gastroenterology, 2003, Volume: 38, Issue:12 Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux	2003
[Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2004, Volume: 43, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Histamine H2 Antagonists; H	2004
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. Journal of pediatric gastroenterology and nutrition, 2005, Volume: 40, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Dose-Response Relatio	2005
Effect of omeprazole on symptoms and ultrastructural esophageal damage in acid bile reflux. World journal of gastroenterology, 2005, Mar-28, Volume: 11, Issue:12 Topics: Adult; Anti-Ulcer Agents; Epithelial Cells; Esophagitis, Peptic; Esophagus; Female; Humans; Male; Mi	2005
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Alimentary pharmacology & therapeutics, 2005, May-15, Volume: 21, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug	2005
[A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2005, Volume: 45, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept	2005
Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World journal of gastroenterology, 2005, May-28, Volume: 11, Issue:20 Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Capsules; Double-Blind Method; Esomeprazole; E	2005
Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Alimentary pharmacology & therapeutics, 2005, Jun-01, Volume: 21, Issue:11 Topics: Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Esophagitis	2005
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re	2005
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Alimentary pharmacology & therapeutics, 2005, Aug-01, Volume: 22, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles;	2005
Management of symptoms in step-down therapy of gastroesophageal reflux disease. Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit	2005
Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Digestive diseases and sciences, 2005, Volume: 50, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disord	2005
[A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2006, Volume: 47, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept	2006
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology, 2006, Volume: 52, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents	2006
A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Digestive diseases and sciences, 2006, Volume: 51, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; E	2006
[Financial restrictions in health care systems could affect treatment quality of GERD-patients]. Zeitschrift fur Gastroenterologie, 2006, Volume: 44, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cost Contro	2006
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office]. MMW Fortschritte der Medizin, 2005, Apr-07, Volume: 147 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Re	2005
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Digestive diseases and sciences, 2006, Volume: 51, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; E	2006
Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. Digestive diseases and sciences, 2006, Volume: 51, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aluminum Hydroxide; Analysis o	2006
Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? The American journal of gastroenterology, 2007, Volume: 102, Issue:6 Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis, Peptic; Female; Gastroesophagea	2007
Reflux oesophagitis in children; the role of endoscopy. A multicentric Italian survey. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39, Issue:9 Topics: Adolescent; Anti-Ulcer Agents; Biopsy; Child; Child, Preschool; Cohort Studies; Endoscopy, Gastroint	2007
[Substituted benzimidazoles--a new dimension in ulcer therapy?]. Wiener klinische Wochenschrift, 1984, Feb-17, Volume: 96, Issue:4 Topics: Benzimidazoles; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esoph	1984
A comparison of five maintenance therapies for reflux esophagitis. The New England journal of medicine, 1995, Oct-26, Volume: 333, Issue:17 Topics: Adult; Anti-Ulcer Agents; Cisapride; Disease-Free Survival; Drug Therapy, Combination; Esophagitis,	1995
[Comparison of the cost-efficacy ratio of omeprazole and ranitidine in the treatment of reflux esophagitis]. Gastroenterologie clinique et biologique, 1995, Volume: 19, Issue:5 Topics: Anti-Ulcer Agents; Endoscopy, Digestive System; Esophagitis, Peptic; Female; Health Care Costs; Huma	1995
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Alimentary pharmacology & therapeutics, 1995, Volume: 9, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Foll	1995
Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Alimentary pharmacology & therapeutics, 1995, Volume: 9, Issue:3 Topics: Adult; Aged; Cisapride; Drug Administration Schedule; Drug Therapy, Combination; Esophagitis, Peptic	1995
A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Alimentary pharmacology & therapeutics, 1995, Volume: 9, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Double-Blin	1995
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study. Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies	1995
Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut, 1995, Volume: 36, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ	1995
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Alimentary pharmacology & therapeutics, 1995, Volume: 9, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Alcohol Drinking; Anti-Ulcer Agents;	1995
Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. Journal of clinical gastroenterology, 1995, Volume: 20, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Double-Blind Method; Esophagitis, Peptic; F	1995
[Comparison of the effects between standard doses of H2-blocker (famotidine 20mg b.d.) and proton pump inhibitor (omeprazole 20mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1994, Volume: 91, Issue:12 Topics: Aged; Aged, 80 and over; Ambulatory Care; Esophagitis, Peptic; Esophagus; Famotidine; Female; Gastri	1994
Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Digestive diseases and sciences, 1995, Volume: 40, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched	1995
Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology, 1994, Volume: 107, Issue:5 Topics: Adolescent; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Female; Gastric Mucosa; Gastrins;	1994
[Reduced ex vivo production of superoxide anion by polymorphonuclear leukocytes during therapy with omeprazole. A pharmacological effect?]. Minerva gastroenterologica e dietologica, 1994, Volume: 40, Issue:3 Topics: Adult; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Neutrophils; Omeprazole; Peptic Ulcer	1994
Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis. Age and ageing, 1994, Volume: 23, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cimetidine; Dose-Response Relationship, Drug; Double-Blind Method; D	1994
Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. The American journal of gastroenterology, 1993, Volume: 88, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Esophagitis,	1993
Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut, 1994, Volume: 35, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy;	1994
Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Administration Sc	1993
Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of disease in childhood, 1993, Volume: 69, Issue:6 Topics: Adolescent; Child; Child, Preschool; Esophagitis, Peptic; Esophagus; Female; Gastric Acidity Determi	1993
Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:1 Topics: Adult; Antacids; Circadian Rhythm; Drug Therapy, Combination; Esophagitis, Peptic; Female; Gastroeso	1993
Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scandinavian journal of gastroenterology, 1993, Volume: 28, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Double-Blind Method; Esophagitis	1993
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies. Alimentary pharmacology & therapeutics, 1993, Volume: 7 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis,	1993
Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scandinavian journal of gastroenterology, 1995, Volume: 30, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Confidence Intervals; Dose-Response Relationship,	1995
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. The New England journal of medicine, 1996, Apr-18, Volume: 334, Issue:16 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cohort Studies; Esophagitis, Peptic;	1996
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 1996, May-15, Volume: 124, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esopha	1996
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut, 1996, Volume: 38, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Esophagoscopy; Female; Gastr	1996
[Effect of elevated head position in bed in therapy of gastroesophageal reflux]. Zeitschrift fur Gastroenterologie, 1996, Volume: 34 Suppl 2 Topics: Adult; Antacids; Anti-Ulcer Agents; Cisapride; Combined Modality Therapy; Esophagitis, Peptic; Femal	1996
Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles;	1996
Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. The American journal of gastroenterology, 1996, Volume: 91, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzy	1996
Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. The American journal of gastroenterology, 1996, Volume: 91, Issue:9 Topics: Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Es	1996
Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. The American journal of gastroenterology, 1996, Volume: 91, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzy	1996
Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Alimentary pharmacology & therapeutics, 1995, Volume: 9, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid	1995
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagit	1996
Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4 Topics: Adult; Double-Blind Method; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Male; Mid	1996
A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointestinal endoscopy, 1996, Volume: 43, Issue:3 Topics: Aged; Anti-Ulcer Agents; Chi-Square Distribution; Chronic Disease; Combined Modality Therapy; Dilata	1996
The use of omeprazole for resistant oesophagitis in children. European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie, 1996, Volume: 6, Issue:4 Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Drug Therapy, Combination; Esophagitis, Pept	1996
Omeprazole in the treatment of patients with complicated gastro-oesophageal reflux disease. Journal of gastroenterology and hepatology, 1996, Volume: 11, Issue:10 Topics: Antacids; Anti-Ulcer Agents; Dilatation; Esophageal Stenosis; Esophagitis, Peptic; Female; Follow-Up	1996
Health-related quality of life of patients with acute erosive reflux esophagitis. Digestive diseases and sciences, 1996, Volume: 41, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Analysis of Variance; Double-Blind Method; E	1996
Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Denmark; Dose-Response R	1996
Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut, 1996, Volume: 39, Issue:5 Topics: Adult; Aged; Anti-Ulcer Agents; Chromogranin A; Chromogranins; Enterochromaffin Cells; Esophagitis,	1996
Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Double-Blind Method; Enzyme Inhibitors;	1997
Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Digestive diseases and sciences, 1997, Volume: 42, Issue:2 Topics: Anti-Ulcer Agents; Child; Child, Preschool; Controlled Clinical Trials as Topic; Esophagitis, Peptic	1997
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. The American journal of gastroenterology, 1997, Volume: 92, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth	1997
Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me	1997
Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:2 Topics: Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Middle Aged; Omep	1997
Omeprazole for severe reflux esophagitis in children. Journal of pediatric gastroenterology and nutrition, 1997, Volume: 24, Issue:5 Topics: Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; F	1997
[Maintenance therapy in reflux esophagitis]. Zeitschrift fur Gastroenterologie, 1997, Volume: 35, Issue:2 Topics: Adult; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Esophagitis, Peptic; Esophagoscopy;	1997
Lansoprazole versus omeprazole in the treatment of reflux esophagitis. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 1997, Volume: 51, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Humans; Lan	1997
Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole--comparison of 24-hour intragastric and oesophageal pH. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Enzyme Inhibito	1997
Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studie	1997
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scandinavian journal of gastroenterology, 1997, Volume: 32, Issue:10 Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Female; G	1997
A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. The American journal of gastroenterology, 1998, Volume: 93, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic	1998
Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment. Italian journal of gastroenterology and hepatology, 1997, Volume: 29, Issue:6 Topics: Adult; Aged; Biopsy; Cimetidine; Drug Administration Schedule; Drug Resistance; Enzyme Inhibitors; E	1997
[Reflux esophagitis; is the preventive eradication of Helicobacter pylori needed in patients on omeprazole?]. Nederlands tijdschrift voor geneeskunde, 1998, Apr-18, Volume: 142, Issue:16 Topics: Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastritis, Atrophic; Gastroesophageal Reflux; Helico	1998
One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz	1997
Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Digestive diseases and sciences, 1998, Volume: 43, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cell Count; Cross-Sectional Studies; Enterochroma	1998
Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid	1998
Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Esophagitis, Peptic; Female; Human	1998
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. European journal of gastroenterology & hepatology, 1998, Volume: 10, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind	1998
Cost and quality effects of treating erosive oesophagitis. A re-evaluation. PharmacoEconomics, 1995, Volume: 8, Issue:2 Topics: Antacids; Anti-Ulcer Agents; Cost of Illness; Costs and Cost Analysis; Decision Trees; Esophagitis,	1995
Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. The American journal of gastroenterology, 1999, Volume: 94, Issue:4 Topics: Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Esophagitis, Peptic; Female; G	1999
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology, 1999, Volume: 117, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Double-Blind Method; Enzyme In	1999
Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. The American journal of gastroenterology, 1999, Volume: 94, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Gastro	1999
Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis? Journal of gastroenterology, 1999, Volume: 34, Issue:4 Topics: Alcohol Drinking; Case-Control Studies; Endoscopy, Digestive System; Enzyme Inhibitors; Esophagitis,	1999
Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen	1999
On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastric	1999
Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen	1999
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Eructati	1999
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. The American journal of gastroenterology, 2000, Volume: 95, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonograph	2000
Pantoprazole versus omeprazole in the treatment of reflux esophagitis. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 1999, Volume: 53, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Fem	1999
Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles;	2000
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut, 2000, Volume: 46, Issue:5 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithrom	2000
Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Dose-Respon	2000
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Digestive diseases and sciences, 2000, Volume: 45, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon	2000
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Human pathology, 2000, Volume: 31, Issue:6 Topics: Adult; Aged; Biopsy; Cysts; Double-Blind Method; Esophagitis, Peptic; Female; Gastric Fundus; Gastri	2000
[Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; En	2000
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:10 Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Hear	2000
Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. The American journal of gastroenterology, 2000, Volume: 95, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Do	2000
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. The American journal of gastroenterology, 2000, Volume: 95, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh	2000
Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. The American journal of gastroenterology, 2000, Volume: 95, Issue:11 Topics: Administration, Oral; Adolescent; Age Factors; Anti-Ulcer Agents; Area Under Curve; Child; Child, Pr	2000
Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. The Journal of pediatrics, 2000, Volume: 137, Issue:6 Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Chronic Disease; Dose-Response Relationship,	2000
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method;	2000
Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth	2001
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz	2001
Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept	2001
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. The American journal of gastroenterology, 2001, Volume: 96, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth	2001
[Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002]. Revue medicale de Liege, 2001, Volume: 56, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Child; Enzyme I	2001
Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. The Laryngoscope, 2001, Volume: 111, Issue:12 Topics: Adult; Esophagitis, Peptic; Female; Gastric Acidity Determination; Humans; Laryngitis; Laryngoscopy;	2001
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis	2002
Integrated acidity and rabeprazole pharmacology. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept	2002
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co	2002
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2002, Volume: 55, Issue:1-2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans;	2002
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2002, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Benzimidazoles; Dyspepsia; Enzyme Inhibi	2002
[Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2002, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Epith	2002
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2002, Volume: 15, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzi	2002
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre t European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz	2002
Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. The American journal of gastroenterology, 2002, Volume: 97, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Double-Blind Metho	2002
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs, 1992, Volume: 44, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer;	1992
Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. Journal of clinical gastroenterology, 1992, Volume: 15, Issue:3 Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Esophagi	1992
Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:3 Topics: Anti-Ulcer Agents; Cisapride; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Middle	1992
Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion. Digestive diseases and sciences, 1992, Volume: 37, Issue:6 Topics: Barrett Esophagus; Drug Administration Schedule; Esophagitis, Peptic; Female; Gastric Acid; Gastroes	1992
Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scandinavian journal of gastroenterology, 1991, Volume: 26, Issue:3 Topics: Adult; Aged; Biopsy; Chi-Square Distribution; Esophagitis, Peptic; Esophagoscopy; Gastric Mucosa; Ga	1991
The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterology clinics of North America, 1990, Volume: 19, Issue:3 Topics: Antacids; Esophagitis, Peptic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Omeprazole	1990
Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists. Alimentary pharmacology & therapeutics, 1990, Volume: 4, Issue:2 Topics: Adult; Aged; Double-Blind Method; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastrins	1990
Australian clinical trials of omeprazole in the management of reflux oesophagitis. Digestion, 1990, Volume: 47 Suppl 1 Topics: Australia; Drug Administration Schedule; Esophagitis, Peptic; Humans; Life Tables; Omeprazole	1990
Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Digestion, 1990, Volume: 47 Suppl 1 Topics: Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Gastric Acidity Determination; Gastric Muco	1990
Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut, 1990, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Cimetidine; Double-Blind Method; Esophagitis, Peptic; Esophagus; Hum	1990
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology, 1990, Volume: 99, Issue:3 Topics: Aged; Chronic Disease; Drug Administration Schedule; Esophagitis, Peptic; Female; Gastrectomy; Gastr	1990
Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut, 1990, Volume: 31, Issue:9 Topics: Cimetidine; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Humans; Male	1990
Clinical experience with omeprazole: assessment of efficacy and safety. Journal of gastroenterology and hepatology, 1989, Volume: 4 Suppl 2 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli	1989
Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Follow-Up Studies; Gastric Acid; Gast	1989
Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Biopsy; Carcinoid Tumor; Cell Division; Cell Transformation, Neoplastic; Enterochromaffin Cells; Eso	1989
Pathophysiology and treatment of gastro-oesophageal reflux disease. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 165 Topics: Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Esophagitis, Peptic; Esophagogastric Junctio	1989
The clinical utility and safety of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic;	1989
Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Esophagitis, Peptic; Gastric Acid; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic; O	1989
[Successful treatment of severe reflux esophagitis with omeprazole: a therapeutic success?]. Zeitschrift fur Gastroenterologie, 1989, Volume: 27, Issue:2 Topics: Clinical Trials as Topic; Esophagitis, Peptic; Follow-Up Studies; Humans; Omeprazole	1989
[Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium]. Gastroenterologie clinique et biologique, 1989, Volume: 13, Issue:5 Topics: Belgium; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Female; France; Humans;	1989
The clinical safety of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Cimetidine; Clinical Trials as Topic; Esophagitis, Peptic; Humans; Liver Function Tests; Omeprazole;	1989
Evaluation of omeprazole in reflux oesophagitis. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Dose-Response Relationship, Drug; Esophagitis, Peptic; Esophagoscopy; Follow-Up Studies; Gastric Aci	1989
Comparison of omeprazole with ranitidine in the treatment of reflux oesophagitis. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Mi	1989
A "significant" new drug for erosive esophagitis and gastroesophageal reflux disease. Oncology (Williston Park, N.Y.), 1989, Volume: 3, Issue:11 Topics: Clinical Trials as Topic; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole	1989
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (London, England), 1987, Feb-14, Volume: 1, Issue:8529 Topics: Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Female; Humans; M	1987
Omeprazole versus ranitidine in erosive oesophagitis. Lancet (London, England), 1987, Sep-12, Volume: 2, Issue:8559 Topics: Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Male; Middle Age	1987
[Omeprazole in the therapy of acid-induced diseases]. Zeitschrift fur Gastroenterologie, 1987, Volume: 25 Suppl 3 Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Eso	1987
[Therapeutic achlorhydria: for which diseases, when and for how long?]. Deutsche medizinische Wochenschrift (1946), 1988, Mar-31, Volume: 113, Issue:13 Topics: Achlorhydria; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Esophagitis, Peptic; Hi	1988
The effects of omeprazole and ranitidine on 24-hour pH in the distal oesophagus of patients with reflux oesophagitis. Alimentary pharmacology & therapeutics, 1988, Volume: 2, Issue:3 Topics: Adult; Aged; Circadian Rhythm; Double-Blind Method; Esophagitis, Peptic; Esophagus; Female; Humans;	1988
Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scandinavian journal of gastroenterology, 1988, Volume: 23, Issue:5 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Esophagitis, Peptic; Female; Humans; Mal	1988
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology, 1988, Volume: 95, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Esop	1988
Omeprazole. Bailliere's clinical gastroenterology, 1988, Volume: 2, Issue:3 Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Sto	1988
Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. British medical journal (Clinical research ed.), 1988, Jan-09, Volume: 296, Issue:6615 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Esophagit	1988
Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Digestive diseases and sciences, 1988, Volume: 33, Issue:5 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Esophagiti	1988
[Omeprazole]. Gastroenterologie clinique et biologique, 1987, Volume: 11, Issue:11 Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esophagit	1987
[Different healing tendencies of reflux esophagitis following omeprazole and ranitidine. Results of a German-Austrian-Swiss multicenter study]. Deutsche medizinische Wochenschrift (1946), 1986, Jan-24, Volume: 111, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as	1986
Comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. The New England journal of medicine, 1986, Mar-13, Volume: 314, Issue:11 Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Double-Blind Method; Esophagit	1986

omeprazole and Esophagitis, Peptic